慢性丁型肝炎患者的干扰素治疗疗程及其对疾病自然病程的影响
基于333例慢性丁型肝炎患者数据库,分析其中99例接受至少6个月干扰素治疗者,中位累积疗程24个月,中位随访55个月。35例获得维持病毒学应答,应答率随疗程延长而增加,5年时达50%。获得维持病毒学应答者肝病死亡或并发症风险低于无应答者,基线肝硬化与无应答预测不良终点。
要点
- 干扰素是慢性丁型肝炎唯一治疗选择,病毒学应答随疗程延长而增加。
- 维持病毒学应答者5年累积概率达50%,肝病死亡或并发症风险低于无应答者。
- 基线肝硬化与无应答预测不良终点,疗程需个体化并仔细评估治疗后反应。
核心结论
- 干扰素病毒学应答随治疗疗程延长而增加,并有利影响疾病自然病程。
- 干扰素治疗疗程必须个体化,并进行仔细的治疗后评估。
研究设计与样本
- 分析慢性丁型肝炎数据库(333例患者,其中161例有干扰素治疗史)。
- 选取99例接受至少6个月干扰素治疗的慢性丁型肝炎患者。
主要发现
- 35例患者获得维持病毒学应答(定义为治疗停止后丁型肝炎病毒RNA阴性持续2年)。
- 累积中位干扰素疗程为24个月(范围6-126个月),中位疗程数2个(范围1-8)。
- 治疗后中位随访55个月(范围24-225个月)。
- 维持病毒学应答的累积概率随疗程延长而增加,5年时达到50%。
- 与未获得维持病毒学应答者相比,获得维持病毒学应答者死于肝病或发生并发症的可能性更低(P=0.032,P=0.006)。
关键数值与推荐
- 维持病毒学应答定义为治疗停止后丁型肝炎病毒RNA阴性持续2年。
- 基线肝硬化预测不良终点的比值比为16.1,对治疗无应答预测不良终点的比值比为5.23。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interferon is the only treatment option in chronic delta hepatitis (CDH). A CDH database (333 patients, 161 with interferon treatment history) was analyzed for effects of treatment duration on virologic response and clinical outcomes. METHODS: Ninety-nine CDH patients who received at least 6 months of interferon were selected. Maintained virologic response (MVR) was defined as hepatitis D virus RNA negative for 2 years after treatment discontinuation. Cumulative median interferon treatment duration was 24 months (range 6-126 months), with a median of 2 courses (range 1-8). Post-treatment median follow-up was 55 months (24-225 months). RESULTS: Thirty-five patients achieved MVR. Cumulative probability of MVR increased with treatment duration and reached 50% at 5 years. Patients with MVR were less likely to die from liver disease or develop complications compared to patients without MVR (P = .032, P = .006, respectively). Cirrhosis at baseline and no response to therapy (odds ratio 16.1 and 5.23, respectively) predicted an adverse endpoint. Hepatitis B surface antigen clearance occurred in 37% of patients with MVR. CONCLUSION: Viral response to interferon increases with treatment duration and favorably affects the natural course of disease. Interferon treatment duration has to be individualized with careful post-treatment assessment.
引用
- Yurdaydin C, Keskin O, Kalkan Ç, et al. Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease. J Infect Dis. 2018. PMID: 29425306. doi:10.1093/infdis/jix656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。